ArticleCureus2026
The Role and Feasibility of Automated Breast Ultrasound in the Evaluation of Male Breast Disease: Workflow Efficiency and Imaging Spectrum.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional hand-held ultrasonography (HHUS) suffers from inherent limitations, including operator dependency, lack of reproducibility, and long acquisition times in busy clinical settings. Automated breast ultrasound (ABUS) addresses these drawbacks by providing standardized, three-dimensional, and operator-independent imaging that separates acquisition from interpretation. While the diagnostic performance of ABUS has been extensively validated for supplemental screening in females with dense breast tissue, its specific application in the male population remains an unexplored frontier in the literature. Objective The objective of this study was to evaluate the diagnostic value, workflow advantages, and imaging spectrum of ABUS in male breast diseases based on a large-scale, single-center experience. Methods This retrospective study included 85 male patients (mean age: 36.6 ± 13.7 years) who underwent ABUS between April 2023 and February 2025. Inclusion criteria focused on symptomatic patients and those requiring high-risk screening or follow-up. Recall rates, complementary imaging frequency, and the Breast Imaging Reporting and Data System or BI-RADS categories were analyzed. Results Breast pain (53 cases, 62.4%) was the most common symptom, and gynecomastia (29 cases, 34.1%) was the most frequent finding. The recall rate for secondary HHUS was 1.2% (1 case). Three biopsies revealed one lipoma, one invasive ductal carcinoma, and one papillary carcinoma. Conclusion ABUS provides a standardized, reproducible evaluation of male breast diseases with minimal recall and optimized workflow efficiency. It serves as a promising adjunct to standard imaging protocols, particularly in younger males where avoiding radiation is preferable, and offers a unique anatomical plane (C-plane).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.